Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of omalizumab (Xolair) in idiopathic refractory severe solar urticaria
2013-004910-16Phase 2Active
- Sponsor
- CHU de Besançon
- Start
- Jun 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of omalizumab in solar urticaria (SU), sponsored by CHU de Besançon. Started Jun 2015; status: active.
02
Drugs
omalizumab
03
Conditions
solar urticaria (SU)
Beyond the preview
Go deeper on 2013-004910-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004910-16.